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 ABSTRACT 
 Background  Systemic lupus erythematosus (SLE) is 
a chronic, multiorgan, autoimmune disease that affects 
people of all ages and ethnicities. 
 Objectives  To explore the relationship between age at 
disease onset and many of the diverse manifestations of 
SLE. Additionally, to determine the relationship between 
age of disease onset and genetic risk in patients with 
SLE. 
 Methods  The relationship between the age at disease 
onset and SLE manifestations were explored in a multi-
racial cohort of 1317 patients. Patients with SLE were 
genotyped across 19 confi rmed genetic susceptibility loci 
for SLE. Logistic regression was used to determine the 
relationships between the number of risk alleles present 
and age of disease onset. 
 Results  Childhood-onset SLE had higher odds of 
proteinuria, malar rash, anti-dsDNA antibody, haemolytic 
anaemia, arthritis and leucopenia (OR=3.03, 2.13, 
2.08, 2.50, 1.89, 1.53, respectively; p values <0.0001, 
0.0004, 0.0005, 0.0024, 0.0114, 0.045, respectively). In 
female subjects, the odds of having cellular casts were 
2.18 times higher in childhood-onset than in adult-onset 
SLE (p=0.0027). With age of onset ≥50, the odds of 
having proteinuria, cellular casts, anti-nRNP antibody, 
anti-Sm antibody, anti-dsDNA antibody and seizures 
were reduced. However, late adult-onset patients with 
SLE have higher odds of developing photosensitivity 
than early adult-onset patients. Each SLE-susceptibility 
risk allele carried within the genome of patients with 
SLE increased the odds of having a childhood-onset 
disease in a race-specifi c manner: by an average of 48% 
in Gullah and 25% in African-Americans, but this was 
not signifi cant in Hispanic and European-American lupus 
patients. 
 Conclusions  The genetic contribution towards 
predicting early-onset disease in patients with SLE is 
quantifi ed for the fi rst time. A more severe SLE phenotype 
is found in patients with early-onset disease in a large 
multi-racial cohort, independent of gender, race and 
disease duration. 
 INTRODUCTION 
 Systemic lupus erythematosus (SLE) is a chronic, 
persistent, autoimmune disease with diverse 
manifestations. It is most common in women of 
reproductive age, but occurs in people of all ages. 
Typically, there is a 9:1 female to male sex bias in 
SLE, and it is still unclear why this phenomenon 
occurs. Evidence suggests that a dose effect of the 
X-chromosome may have a role in this female pre-
ponderance as can be seen by the increased preva-
lence of SLE in male subjects with Klinefelter’s 
disease (47, XXY).  1  There is also strong evidence 
that genetics have a critical role in the pathogen-
esis of SLE, as can be seen in the strong familial 
aggregation of this disease.  2  –  4  SLE disease sever-
ity varies profoundly by race.  5    6  Disease onset 
occurs in adolescence in approximately 15–20% of 
patients, and is known to be more aggressive than 
adult-onset SLE.  7    8  It is understood that SLE disease 
manifestations accumulate with increasing disease 
duration.  9  
 Herein, we explore the independent association 
of the age at SLE onset with the many clinical and 
serological manifestations of the disease in a large 
patient cohort. We further examine the relation-
ship between genetic risk for SLE and patient’s age 
at disease onset. Our data indicate that early dis-
ease onset is associated with a more severe phe-
notype in patients with SLE. We also show that 
childhood-onset disease is predicted by the pres-
ence of more genetic susceptibility loci for SLE 
compared with adult-onset disease in patients of 
African descent. 
 PATIENTS AND METHODS 
 Patients and clinical data 
 Our study population included 1317 patients 
with SLE enrolled in the Lupus Family Registry 
and Repository (LFRR) at the Oklahoma Medical 
Research Foundation. Patient enrolment in the 
LFRR has previously been described.  4  All patients 
met at least four of the 11 American College of 
Rheumatology criteria for classifi cation of SLE.  10    11  
Patients completed a questionnaire that described 
their disease history. Medical records were also 
obtained, and relevant information was extracted 
and reviewed by a nurse, doctor’s assistant, or a 
doctor. Age of disease onset was determined as 
the age at which the fourth American College 
of Rheumatology SLE criterion had been met 
( table 1 ). Race was self-reported. Our study popu-
lation included 43% European-American, 27% 
 African-American, 12% Hispanics, 10% Gullah, 
5% Native-American and 2% Asian lupus patients. 
Principal component analysis (PCA) was used to 
determine population substructure as described 
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previously confi rmed in lupus patients was selected for geno-
typing, except for the human leucocyte antigen region and 
interferon regulatory factor 5 as they are known to harbour 
multiple independent genetic effects. For the HLA region, 
the two SNPs that were recently shown to have independent 
genetic effects using logistic regression analysis of a large 
number of lupus- associated SNPs in the HLA region  13  were 
genotyped in our study. In the interferon regulatory factor 5 
locus, three independent genetic effects have been previously 
identifi ed,  14  and three tag SNPs representing these indepen-
dent effects were genotyped in our study. 
 Genotyping was performed using the Illumina iScan System 
and Illumina Infi nium II genotyping assays following the manu-
facturer’s recommendations. Genotyping success rate ranged 
between 97.6% and 100% for the 19 SNPs genotyped. The 
total number of SLE-risk alleles within all 19 loci genotyped was 
determined in each female patient with SLE using an additive 
model. Patients with any undetermined genotype were excluded 
from the analysis. 
 Statistical analyses 
 Univariable analyses were performed on the age of disease 
onset and the various clinical and serological disease manifes-
tations. Fisher’s exact tests were performed on manifestations 
with a 2 × 2 table cell value with an expected value <5. These 
manifestations were excluded from any further analysis owing 
to sample-size constraints. SLE disease manifestations with 
p values <0.20 were further characterised. 
 We fi tted two logistic regression models for each SLE disease 
manifestation: one for childhood-onset (<18 years at onset) ver-
sus adult-onset disease (≥18 years at onset), and one for early 
adult-onset (18–49 years at onset) versus late adult-onset disease 
(≥50 at onset). Each logistic regression model included the dis-
ease manifestation as the dependent variable, and age of onset 
as the independent variable of interest, while controlling for 
gender, race and disease duration. We also tested for interac-
tion between age of onset and gender, and fi t separate models 
for male subjects and female subjects as needed. Patients of 
native Hawaiian, historic Asian, or Pacifi c Islander descent were 
not included in the regression analyses because of sample size 
constraints. 
 We compared gender distributions between patients with 
childhood-onset SLE and patients with early adult-onset disease 
using the χ 2 test. We similarly compared the distribution of gen-
der for patients with late adult-onset SLE versus patients with 
early adult-onset disease. 
 Logistic regression was also used to compare the number of 
SLE risk alleles between childhood-onset and adult-onset dis-
ease in female patients with SLE. To account for confounding 
population substructure or admixture in the studied population 
we employed PCA using genotyping data from 107 ancestry 
informative markers. We identifi ed one outlier individual who 
was excluded from the analysis, and a second individual who 
was self-reported as American Indian or Alaskan Native but 
clustered as Hispanic, and thus was analysed as Hispanic in 
assessing gene risk for SLE. 
 Linear regression assessed the association between the num-
ber of SLE risk alleles and the age of disease onset. The number 
of risk alleles was the dependent variable and the age at onset 
was the independent variable. Each race was modelled indepen-
dently as there was evidence of interaction between races. All 
linear modelling assumptions were assessed and met. 
 Statistical analysis was performed using SAS v9.1.3. 
below, and outliers were identifi ed before genetic data analysis. 
Our studies were approved by the institution review boards of 
our institutes and each patient signed a written informed con-
sent before participation in this study. 
 Serology 
 Serum was obtained from all patients upon LFRR enrol-
ment. All serological testing was performed at the Oklahoma 
Medical Research Foundation clinical immunology laboratory. 
Oüchterlony immunodiffusion assays were performed to assess 
the presence of extractable nuclear antigens (anti-Sm, nRNP, 
Ro, La, ribosomal P).  12  Anti-dsDNA antibodies were assayed 
using indirect immunofl uorescence by  Crithidia luciliae (Inova 
Diagnostics, San Diego, California, USA). The presence of IgG 
and IgM anticardiolipin antibodies (anti-aCL) was determined 
by ELISA. 
 Genetic susceptibility quantifi cation 
 Female patients with SLE were genotyped for 19 common 
single nucleotide polymorphisms (SNPs) that represent con-
fi rmed SLE susceptibility loci ( table 2 ). These represent com-
mon genetic susceptibility loci that have been confi rmed in 
at least two independent cohorts of lupus patients and con-
trols. Rare variants such as susceptibility loci in TNFAIP3 and 
TREX1 were not examined. For each genetic susceptibility 
locus examined, a representative associated SNP that has been 
 Table 2  Single nucleotide polymorphisms (SNPs) representing 
19 previously established and confi rmed independent susceptibility loci 
for systemic lupus erythematosus that were genotyped in our study 
population 
 Gene/region  Chromosome  Genotyped SNP  Risk allele 
BANK1 4q24 rs10516487 G
C8orf13-BLK 8p22–23 rs13277113 A
CTLA4 2q33 rs231775 G
FCGR2A 1q23 rs1801274 C
HLA region 1 6p21.33 rs3131379 A
HLA region 2 6p21.32 rs1270942 G
IL21 4q26 rs907715 G
IRF5 7q32 rs729302 A
IRF5 7q32 rs10954213 A
IRF5 7q32 rs2070197 C
ITGAM 16p11.2 rs1143679 A
KIAA1542 11p15.5 rs4963128 C
MBL 10q11 rs1800450 A
MECP2 Xq28 rs17435 T
PDCD1 2q37.3 rs11568821 A
PTPN22 1p13 rs2476601 A
PXK 3p14.3 rs6445975 C
STAT4 2q32.2 rs7574865 T
TNFSF4 1q25 rs2205960 T
 HLA, human leucocyte antigen; IRF5, interferon regulatory factor 5. 
 Table 1  Age at disease onset and gender distribution of the lupus 




 Male  Female 
 N (% of group)  N (% of group) 
<18  20 (18.0)   91 (82.0) 111
18–49  83 (8.0)  955 (92.0) 1038
≥50  23 (13.7)  145 (86.3) 168
Total (%) 126 (9.6) 1191 (90.4) 1317
25_annrheumdis141697.indd   152 12/2/2010   10:11:21 PM
 group.bmj.com on November 15, 2012 - Published by ard.bmj.comDownloaded from 
Extended report
Ann Rheum Dis 2011;70:151–156. doi:10.1136/ard.2010.141697 153
 It should be noted that the serological data we used in this 
study are based on a single serum sample obtained at the time of 
patient enrolment in LFRR. Given possible fl uctuation in autoan-
tibody levels in lupus patients, data for autoantibody associa-
tions should be replicated to be considered confi rmed. 
 Gender proportions are not equal across our population of 
patients with SLE ( table 1 ). Specifi cally, the proportion of male 
subjects is 10.0% higher in the group of patients with age of 
onset <18 years than in the 18–49-year-old age group (χ 2 =12.34, 
p=0.0004). The proportion of male subjects is 5.7% higher in the 
≥50 age group than in the 18–49 year-old age group (χ 2 =5.85, 
p=0.0156). 
 We next hypothesised that childhood-onset SLE is associated 
with higher genetic risk for the disease, which might explain 
a more severe disease than with adult-onset disease. We cal-
culated the total number of SLE-risk alleles by genotyping 
19 SNPs that represent 19 independent previously confi rmed 
genetic susceptibility loci for SLE. PCA was used to identify 
outliers and then lupus genetic risk analysis was performed in 
each race separately. We found a signifi cant difference in the 
number of carried SLE risk alleles between childhood-onset 
and adult-onset disease in Gullah and African-American lupus 
patients with odds ratios (95% CI) of 1.48 (1.07 to 2.04) and 
1.25 (1.02 to 1.54), and p values of 0.018 and 0.032, respectively. 
These data indicate that for each additional risk allele car-
ried, the odds of developing SLE during childhood (<18 years) 
increases by an average of 48% per risk allele in Gullah patients 
with SLE, and 25% in African-American patients. There was 
no association between the number of lupus risk alleles and 
age of disease onset in Hispanic patients, although a similar 
trend was observed (OR=1.21 (0.98 to 1.50), p=0.075). There 
was no association between the number of SLE risk alleles 
and age of disease onset in European-American lupus patients 
( fi gure 1 , online supplementary  table 1 ). These fi ndings were 
 RESULTS 
 Malar rash, arthritis, proteinuria, cellular casts, haemolytic 
anaemia and anti-dsDNA and anti-nRNP antibodies were all 
independently associated with the age of disease onset when 
comparing childhood-onset with adult-onset SLE ( table 3 ). 
Photosensensitivity, oral ulcers, pericarditis, proteinuria, cellu-
lar casts, seizures, thrombocytopenia and anti-dsDNA, anti-Sm, 
and anti-nRNP antibodies were all independently associated 
with the age of disease onset when comparing early and late-
adult onset SLE ( table 3 ). 
 After adjusting for gender, race and disease duration, the 
odds of having proteinuria, malar rash, anti-dsDNA antibodies, 
haemolytic anaemia, arthritis and leucopenia were all higher 
in childhood-onset than in adult-onset SLE ( table 4 ). The dif-
ferences in the frequency of proteinuria, malar rash, anti-
 dsDNA antibodies and haemolytic anaemia survive a stringent 
Bonferroni corrected p value of <0.004. There was an interac-
tion between the age of onset and gender when modelling for 
cellular casts. In male subjects, although not signifi cant, the 
odds of having cellular casts were higher in adult-onset than in 
childhood-onset SLE. In female subjects, the odds of having cel-
lular casts were higher in childhood-onset than in adult-onset 
SLE (p=0.0027). 
 The odds of having proteinuria, cellular casts, anti-nRNP 
antibody, anti-Sm antibody, anti-dsDNA antibody and sei-
zures were higher in early adult-onset than in late adult-onset 
disease after adjusting for gender, race and disease duration, 
while late adult-onset patients with SLE had higher odds of 
developing photosensitivity than patients with early adult-
 onset disease ( table 4 ). The difference in the frequency of 
renal involvement in early adult-onset compared with late 
adult-onset disease, as indicated by the presence of proteinu-
ria and cellular casts, survive a Bonferroni corrected p value of 
<0.004 ( table 4 ). 
 Table 3  Univariable analyses comparing age at onset and the clinical and serological manifestations of SLE 
 <18 versus ≥18 
 95% CI 
 18–49 versus ≥50 
 95% CI 
 χ  2   OR  LL  UL  p Value  χ  2   OR  LL  UL  p Value 
Clinical features Clinical features
 Malar rash 16.77 2.25 1.51 3.34 <0.0001  Malar rash 2.51 1.32 0.94 1.86 0.1133
 Discoid rash 0.01 0.98 0.56 1.70 0.9404  Discoid rash 1.20 1.32 0.80 2.17 0.2738
 Photosensitivity 0.75 1.19 0.80 1.77 0.3867  Photosensitivity 7.50 0.63 0.46 0.88 0.0062
 Oral ulcer 0.57 1.17 0.77 1.78 0.4500  Oral ulcer 4.64 1.53 1.04 2.25 0.0312
 Arthritis 4.11 1.62 1.01 2.58 0.0426  Arthritis 2.17 1.29 0.92 1.82 0.1408
 Pericarditis 1.80 1.37 0.86 2.18 0.1801  Pericarditis 4.32 1.66 1.02 2.69 0.0378
 Pleuritis 0.62 1.18 0.78 1.80 0.4329  Pleuritis 2.24 1.34 0.91 1.96 0.1344
 Proteinuria 36.10 3.34 2.21 5.03 <0.0001  Proteinuria 40.33 3.80 2.46 5.88 <0.0001
 Cellular casts 9.91 2.04 1.30 3.21 0.0016  Cellular casts 19.42 5.36 2.34 12.31 <0.0001
 Seizures 1.33 1.45 0.77 2.74 0.2487  Seizures 6.15 3.02 1.21 7.55 0.0131
 Psychosis  0.51   0.5770*  Psychosis  2.15   0.2580*
 Leucopenia 3.11 1.43 0.96 2.12 0.0780  Leucopenia 2.37 1.33 0.93 1.90 0.1234
 Lymphopenia 0.26 1.11 0.75 1.64 0.6130  Lymphopenia 1.42 1.23 0.88 1.72 0.2342
 Thrombocytopenia 3.04 1.52 0.95 2.43 0.0814  Thrombocytopenia 5.15 1.83 1.08 3.09 0.0233
 Haemolytic anaemia 12.94 2.73 1.55 4.81 0.0003  Haemolytic anaemia 0.71 1.38 0.65 2.93 0.3993
Autoantibodies Autoantibodies
 Anti-dsDNA 11.22 1.95 1.31 2.90 0.0008  Anti-dsDNA 5.98 1.64 1.10 2.44 0.0144
 Anti-Sm 0.85 0.69 0.31 1.52 0.3576  Anti-Sm 5.35 2.45 1.12 5.37 0.0208
 Anti-nRNP 5.37 0.53 0.31 0.91 0.0205  Anti-nRNP 5.03 1.62 1.06 2.47 0.0249
 Anti-Ro 0.71 0.81 0.49 1.33 0.3992  Anti-Ro 0.08 0.95 0.64 1.39 0.7818
 Anti-La 0.25 0.79 0.31 2.00 0.6173  Anti-La 1.62 0.67 0.36 1.25 0.2035
 Anti-ribosomal P  0.51   1.0000*  Anti-ribosomal P  0.97   1.0000*
 aCL IgG 1.74 1.31 0.88 1.95 0.1875  aCL IgG 1.43 1.24 0.87 1.78 0.2313
 aCL IgM 0.06 1.09 0.57 2.08 0.8061  aCL IgM 0.18 1.13 0.63 2.04 0.6739
 *Fisher’s exact two-tailed p value. 
 aCL, anticardiolipin antibodies, LL, lower limit; SLE, systemic lupus erythematosus; UL, upper limit. 
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antibodies all being more prevalent in childhood-onset SLE than 
in adult-onset disease. Their study failed to detect differences in 
the prevalence of malar rash, arthritis or leucopenia, probably 
owing to the much smaller sample size (56 childhood-onset and 
194 adult-onset patients with SLE), and inability to control for 
other known confounders such as gender, race and disease dura-
tion. Our study fails to extend the association they found with 
anti-ribosomal P autoantibodies in childhood-onset disease. 
 Kidney involvement and damage has repeatedly been reported 
to have a higher prevalence in patients with SLE with disease 
onset during childhood.  8    16    17  These reports are consistent with 
our fi ndings. Our work further characterises kidney involve-
ment and reports the effects of the age at onset after accounting 
for confounding gender, race and disease duration. In adult-
further confi rmed using linear regression and modelling each 
race individually to test if the age at disease onset predicts the 
number of risk alleles present in female patients with SLE ( fi g-
ure 2 , online supplementary  table 2 ). 
 DISCUSSION 
 We report the effect of age at disease onset on the various SLE 
manifestations in a large cohort of racially divergent patients 
with SLE. Childhood-onset SLE is associated with a more severe 
disease with higher odds of proteinuria, malar rash, anti-dsDNA 
antibody, haemolytic anaemia, arthritis and leucopenia than 
adult-onset disease. 
 A recent study by Hoffman  et al  15  in 2009 had similar fi ndings 
for proteinuria, cellular casts, haemolytic anaemia and dsDNA 
 Figure 1  Estimated probability of childhood-onset systemic lupus erythematosus (SLE) predicted by the number of risk alleles present. Logistic 
regression modelling depicting the probability of developing childhood-onset SLE based on the number of SLE susceptibility alleles carried in patients 
who are European-American (green), African-American (red), Hispanic (purple), and Gullah (blue). The number of SLE risk alleles is associated with the 
development of childhood-onset disease in Gullah and African-American, but not in Hispanic and European-American patients with SLE. 
 Table 4  Multivariable analysis comparing age at SLE onset and the clinical and serological manifestations with univariable analysis p values <0.20 
 <18 versus ≥18 
 95% CI 
 18–49 versus ≥50 
 95% CI 
 χ  2   OR  LL  UL  p Value  χ  2   OR  LL  UL  p Value 
Proteinuria 23.90 3.03 1.94 4.72 <0.0001 Proteinuria 22.24 2.98 1.89 4.68 <0.0001
Malar rash 12.65 2.13 1.40 3.23 0.0004 Cellular casts 10.38 4.00 1.72 9.30 0.0013
Anti-dsDNA 12.17 2.08 1.38 3.14 0.0005 Photosensitivity 6.70 0.63 0.45 0.89 0.0097
Haemolytic anaemia 9.18 2.50 1.38 4.52 0.0024 Anti-nRNP 6.44 1.82 1.15 2.89 0.0112
Arthritis 6.40 1.89 1.15 3.09 0.0114 Anti-Sm 6.11 2.77 1.24 6.20 0.0134
Leucopenia 4.04 1.53 1.01 2.31 0.0445 Anti-dsDNA 5.37 1.62 1.08 2.45 0.0205
Anti-nRNP 2.67 0.61 0.34 1.10 0.1020 Seizures 4.98 2.88 1.14 7.29 0.0256
Pericarditis 1.44 1.34 0.83 2.17 0.2301 Oral ulcer 3.47 1.46 0.98 2.18 0.0624
Thrombocytopenia 0.86 1.26 0.77 2.07 0.3550 Thrombocytopenia 3.42 1.67 0.97 2.87 0.0645
aCL IgG 0.44 1.15 0.76 1.75 0.5094 Malar rash 2.01 1.30 0.91 1.86 0.1564
      Pericarditis 1.97 1.43 0.87 2.34 0.1608
Cellular casts Arthritis 1.49 1.25 0.88 1.78 0.2224
 Men 1.05 0.40 0.07 2.31 0.3057 Pleuritis 1.15 1.24 0.84 1.84 0.2841
 Women 9.01 2.18 1.31 3.64 0.0027 Leucopenia 0.51 1.15 0.79 1.67 0.4751
 Adjusted for gender, race and disease duration. p Values are reported without correction for multiple testing.
With a Bonferroni correction a p value of <0.004 is considered signifi cant. p Values <0.05 were considered highly suggestive. 
 aCL, anticardiolipin antibodies; LL, lower limit; SLE, systemic lupus erythematosus; UL, upper limit. 
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the late adult-onset group than in early adult-onset SLE in this 
population. 
 We report a higher genetic risk in childhood-onset disease 
than in adult-onset disease in Gullah and African-American 
patients with SLE. Our fi ndings suggest that genetic risk has 
a role in determining age of disease onset in patients with SLE 
of African descent, which is an important predictor of disease 
severity. However, it should be noted that the absolute differ-
ence in the number of risk alleles between childhood-onset and 
adult-onset disease is rather small, refl ecting the fact that the 
confi rmed SLE genetic susceptibility loci known to date, and 
which were largely discovered by genotyping common genetic 
variants, explain only a small fraction of the genetic risk for 
SLE. We suspect that different susceptibility genes for SLE con-
tribute variable proportions towards the overall genetic risk for 
the disease in different races. This might explain why we did 
not see an association between the age of disease onset and 
genetic risk in patients of European descent. It is also plausible 
that the correlation between increased genetic risk and earlier 
onset of the disease in Gullah and African-American patients 
refl ects a typically more severe disease in this group. 
 Although most of the known SLE genetic susceptibility loci 
were discovered in European-derived patients, more stud-
ies to investigate the genetic basis of SLE in minority popula-
tions, including African-Americans are underway. We believe 
that the initial discovery of genetic effects requires less rigor-
ous genotyping in European-derived populations, owing to 
relatively larger haplotype blocks. More dense genotyping 
in African-derived populations is more likely to help localise 
these genetic effects to smaller regions in the genome, owing 
to relatively smaller haplotype blocks in African populations. 
Increased severity of SLE in African-Americans compared with 
European-Americans is well recognised. This suggests that dif-
ferences in genetic susceptibility might account for differences 
onset SLE, patients with a disease onset at <50 years of age are 
about three to four times more likely to have renal involvement 
than patients with a disease onset ≥50 years of age. Our data are 
consistent with previous reports that fi nd renal involvement less 
common in SLE onset after age 50.  18  –  21  
 Patients in our study population with SLE onset ≥50 years 
were 1.59 times as likely to develop photosensitivity, com-
pared with SLE onset 18–49 years. This fi nding opposes that of 
Wang  et al  22  in a study of 695 Chinese patients with SLE where 
they observed photosensitivity in 16.3% of late-onset and 29.3% 
of early-onset SLE cases. These differences are probably due to 
race, as our population has <2% Asian composition. 
 In 2006, Bertoli  et al  19  reported that patients with SLE with 
late disease onset (≥50 years) were 2.82 times as likely to have 
neurological involvement after adjusting for gender. We reached 
different conclusions and found that patients with early adult-
onset disease were nearly three times as likely to have a his-
tory of seizures. We were unable to fi nd any association with 
psychosis. These differences might be due to their inclusion 
of headaches and neurocognitive impairment as neurological 
involvement. Our data do, however, agree with their fi ndings 
that the odds of having anti-Sm antibodies are much higher in 
patients with SLE onset before age 50.  19  
 One fi nding that is particularly interesting is that the odds of 
having anti-nRNP antibodies are higher in adult-onset than in 
childhood-onset SLE. Also, in adult-onset SLE, the odds of hav-
ing anti-nRNP antibodies are 1.82 times higher in early adult 
than in late adult-onset disease. These data suggest that female 
sex hormones may have a role in the production of these 
autoantibodies. Indeed, Furukawa  et al  23  demonstrated the 
enhanced binding of keratinocytes to anti-nRNP upon stimula-
tion with β-oestradiol. We also observe a shift in the SLE sex 
bias of our population. The proportion of female subjects is 
10% lower in the childhood-onset group, and 5.7% lower in 
 Figure 2  Estimated number of systemic lupus erythematosus (SLE) risk alleles present as predicted by the age of disease onset. Linear regression 
analysis showing signifi cant reduction in the number of risk alleles needed to develop SLE with increase age at disease onset in Gullah (blue) and 
African-American (red) patients with SLE (p=0.0044 and 0.011, respectively), but not Hispanic (purple) or European-American (green) patients 
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in the clinical phenotype of the disease, in addition to the differ-
ence in disease prevalence, which is more common in African-
Americans than in European-Americans. Our data suggest that 
increased genetic susceptibility predicts an earlier disease onset 
in African-derived but not European-derived patients. This is 
consistent with a more severe disease in African-derived patients 
and in childhood-onset disease. Of interest, it appears that the 
association between increased genetic risk and childhood-onset 
disease is proportional to the African component of the popula-
tion studied, being highest in Gullah patients compared with 
African-American patients who have more European admix-
ture. This effect then disappears in the European-American 
patients who have no or minimal African admixture. 
 We suggest a model that predicts the onset of SLE as a factor 
of both SLE susceptibility genetic background and environmen-
tal factors. We propose that the presence of higher genetic sus-
ceptibility for the disease lowers the threshold to develop SLE, 
allowing for earlier disease onset in the presence of necessary 
environmental triggers. To our knowledge, our data represent the 
fi rst quantitative evidence in any complex autoimmune disease to 
indicate that increased genetic susceptibility is associated with an 
early disease onset. These data were confi rmed in two indepen-
dent cohorts of Gullah and African-American patients with SLE. 
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